公开(公告)号：US20220072012A1

公开(公告)日：2022-03-10

申请号：US17414285

申请日：2019-12-17

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Masatomo KATO ,  Tomoko ODA ,  Kazutaka KIDO

IPC分类号： A61K31/575 ,  A61K9/00 ,  A61P27/10

摘要： The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210059997A1

公开(公告)日：2021-03-04

申请号：US16958571

申请日：2018-12-27

申请人： UNIVERSITY OF FUKUI ,  SANTEN PHARMACEUTICAL CO., LTD.

发明人： Masaya OKI ,  Fumito KANADA ,  Kazuma KAMATA ,  Yoshihiro TAKAMURA ,  Seiji MIYAKE ,  Masaru INATANI ,  Hiroyuki UCHIDA ,  Miho NOGATA ,  Masatomo KATO ,  Koushi FUJISAWA ,  Shinji TAKAOKA

IPC分类号： A61K31/4439 ,  A61K31/192 ,  A61K9/00 ,  A61P27/12 ,  A61K31/4406

摘要： Provided are agents for prevention and therapeutic treatment of cataract that act by a different mechanism from conventional agents, and use of a PPAR activator for production of such agents. An agent for prevention and/or therapeutic treatment of cataract, containing a PPAR activator as an active ingredient, is used.

公开(公告)号：US20190255026A1

公开(公告)日：2019-08-22

申请号：US16405249

申请日：2019-05-07

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Hideki MIYAKE ,  Tomoko ODA ,  Daisuke SHII

IPC分类号： A61K31/436 ,  A61K9/00 ,  A61K31/675

摘要： A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.

公开(公告)号：US20190106393A1

公开(公告)日：2019-04-11

申请号：US16210163

申请日：2018-12-05

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Kenji KAWASHIMA ,  Yusuke YAMAZAKI ,  Shinji TAKAOKA ,  Daisuke SHII ,  Tomoko ODA ,  Takahiro MATSUYAMA

IPC分类号： C07D241/44 ,  C07F9/6509 ,  A61P29/00 ,  A61P27/02 ,  C07D403/12 ,  A61K31/675 ,  A61K31/5377 ,  A61K31/498

CPC分类号： C07D241/44 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/675 ,  A61P27/02 ,  A61P29/00 ,  C07D403/12 ,  C07F9/650994

摘要： The present invention relates to defined quinoxalin-2-one compounds or a pharmaceutically acceptable salt or a hydrate or a solvate thereof. The compounds, salts or hydrates have a glucocorticoid receptor agonist activity, and are useful as a medicine, in particular as a prophylactic or therapeutic agent for a glucocorticoid receptor related disease.

公开(公告)号：US20180246081A1

公开(公告)日：2018-08-30

申请号：US15964210

申请日：2018-04-27

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Hideki MIYAKE ,  Tomoko ODA

IPC分类号： G01N33/50 ,  A61K31/7052 ,  A01K67/027 ,  A61K45/00

CPC分类号： G01N33/5088 ,  A01K67/027 ,  A01K2207/25 ,  A01K2227/105 ,  A01K2267/035 ,  A61K31/7052 ,  A61K45/00 ,  G01N33/5082 ,  G01N2500/10 ,  G01N2800/162

摘要： A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.

公开(公告)号：US20180169079A1

公开(公告)日：2018-06-21

申请号：US15895100

申请日：2018-02-13

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Naveed SHAMS ,  Henk-Andre KROON ,  Hisashi KAWATA ,  Noriko KAWABATA

IPC分类号： A61K31/444 ,  A61K9/00

CPC分类号： A61K31/444 ,  A61K9/0048 ,  A61P27/02 ,  A61P27/06

摘要： Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.

公开(公告)号：US09999593B2

公开(公告)日：2018-06-19

申请号：US12995351

申请日：2009-05-28

申请人： Timo Reunamaki ,  Pertti Pellinen ,  Olli Oksala ,  Kari Lehmussaari

发明人： Timo Reunamaki ,  Pertti Pellinen ,  Olli Oksala ,  Kari Lehmussaari

IPC分类号： A61K31/5575 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/02 ,  A61K9/00 ,  A61K9/08

CPC分类号： A61K9/0048 ,  A61K9/08 ,  A61K31/5575 ,  A61K47/02 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  Y02A50/465

摘要： The present invention relates to an ophthalmic aqueous composition containing PGF2α analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogs in an aqueous composition.

公开(公告)号：US09987128B2

公开(公告)日：2018-06-05

申请号：US14655787

申请日：2013-12-27

申请人： Santen Pharmaceutical Co., Ltd.

发明人： Christian Winfried Wagner ,  Yoshitaka Yamada ,  Katsuyuki Ueno

IPC分类号： A61F2/16

CPC分类号： A61F2/1678 ,  A61F2/167

摘要： Provided is an intraocular lens injector that allows a haptic and a optic to be pushed in reliably. The intraocular lens injector includes a lens holder holding an intraocular lens which has a optic and a haptic extending in a curved shape from the optic, a device body to which the lens holder is attached, a plunger inserted projectably/retractably in the device body and coming into contact with the intraocular lens to push out this intraocular lens, and a nozzle portion connected to the device body, the nozzle portion releasing the intraocular lens while folding the intraocular lens concavely by a push-in operation of the plunger. A positioner is provided to push up the haptic along a thickness direction of the optic within a range contactable with a distal end of the plunger, when the lens holder and the intraocular lens are attached to the device body.

公开(公告)号：US20170340644A1

公开(公告)日：2017-11-30

申请号：US15523970

申请日：2015-11-05

申请人： SANTEN PHARMACEUTICAL CO., LTD. ,  DAIICHI SANKYO COMPANY, LIMITED

发明人： Yoko ENDO ,  Kyohei TAKAHASHI ,  Shinya UMEZAKI

IPC分类号： A61K31/538 ,  A61K31/496 ,  A61K9/08 ,  A61K31/573 ,  A61K47/10 ,  C07J5/00 ,  C08G65/00 ,  C07C31/18

摘要： An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.

公开(公告)号：US09827139B2

公开(公告)日：2017-11-28

申请号：US14437577

申请日：2013-10-28

申请人： Santen Pharmaceutical Co., Ltd.

发明人： Christian Winfried Wagner ,  Yoshitaka Yamada ,  Katsuyuki Ueno

IPC分类号： A61F2/16 ,  A61F9/00

CPC分类号： A61F9/0017 ,  A61F2/167 ,  F04C2270/0421

摘要： An intraocular lens injector includes a lens holder holding an intraocular lens which has an optic and a haptic extending in a curved shape from the optic, a plunger which comes into contact with the intraocular lens and pushes out the intraocular lens, and a device body in which the plunger is inserted projectably/retractably and in which the lens holder can be attached in an intersecting direction relative to an axis of the plunger. The lens holder includes a position regulating portion for regulating a disposing position of the haptic in such a manner that a distal end of the plunger at an initial position before the plunger is pushed in and the optic may be laid on a common plane with a portion of the haptic lying on top of the plunger.